&Partners’s Galectin Therapeutics GALT Stock Holding History

&Partners’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-41,000	Closed	-$114K	–	2533
2026 Q1	$114K	Buy	+41,000	New	+$125K	﹤0.01%	2327

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

&Partners's GALT Position: Q2 2026 in Review

&Partners sold out of Galectin Therapeutics (GALT) in Q2 2026, closing a stake of 41,000 shares — an estimated $114K sold.

&Partners first reported a position in GALT in Q1 2026 and held it in 1 quarter. The position peaked at $114K in Q1 2026. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

&Partners reported no remaining Galectin Therapeutics position as of Q2 2026 after selling out during the quarter.
&Partners sold 41,000 Galectin Therapeutics shares in Q2 2026, an estimated $114K.
&Partners first reported a position in Galectin Therapeutics in Q1 2026 and held it in 1 quarter.
&Partners's Galectin Therapeutics position peaked at $114K in Q1 2026.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.